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ABSTRACT
Introduction: There is scarce information
about right ventricle (RV) function in patients
with secondary pulmonary hypertension (PH)
undergoing transcatheter aortic valve implan-
tation (TAVI). We aim to identify possible RV
abnormalities in patients referred for TAVI with
severe aortic stenosis (sAS) and secondary PH.
Methods: Objective measures of RV function,
as well as noninvasive estimates of pulmonary
artery systolic pressures (PASP) were obtained
from 30 sAS patients undergoing percutaneous
valve intervention.
Results: Sixteen (53%) evaluated patients had
some degree of PH. As expected, left ventricular
mass index (281 ± 75 g/m2) and left atrial vol-
ume index (89 ± 23 mL/m2) values were signif-
icantly elevated. Even though RV end-systolic
(8 ± 4 cm2) and end-diastolic (17 ± 4 cm2) areas
were normal as well as RV fractional area
change values (57 ± 16%); both longitudinal
measures of RV systolic function such as tri-
cuspid annular plane systolic excursion
(1.9 ± 0.5 cm) and systolic velocity (10 ± 2 cm/
s) were clearly reduced with just mild elevations
in PASP (54 ± 7 mmHg).
Conclusions: Subclinical RV dysfunction is
present in patients with sAS and secondary PH
undergoing TAVI. Whether longitudinal mea-
sures of RV systolic function could predict
clinical outcomes in these patients needs to be
further explored.
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INTRODUCTION
Improved survival of the population has raised
our attention to degenerative calcified aortic
stenosis (AS), the most common form of
acquired valvular heart disease in the Western
world. Depending on the source, from 3% to 7%
of patients older than 65 years of age has a
moderate to severe degree of AS; a prevalence
that is projected to increase with aging of the
population [1].
Since symptomatic severe AS is lethal with
high 2-year mortality, surgical aortic valve
replacement has been traditionally offered to
these patients in order to improve survival.
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However, up to 50% of patients with symp-
tomatic AS are usually not referred to a surgeon
due to the presence of significant comorbidities
[2]. Moreover, older age and left ventricular
dysfunction have been reported as additional
reasons for which patients were denied surgery
rather than their associated comorbidities.
The advent of transcatheter aortic valve
implantation (TAVI) procedures has broadened
the opportunity to many patients to undergo
this intervention if considered at high risk for
traditional surgical replacement. In a recent
review, surgery for AS and TAVI were compared
and TAVI was found to have similar or better
early and midterm outcomes for adults with AS,
including those at low to intermediate risk [3].
Therefore, it is important to characterize better
these patients in order to determine which
patients would benefit the most.
Most recently, right ventricular (RV)
dilatation has been associated with postoper-
ative outcomes in patients undergoing TAVI.
Furthermore, in inoperable AS patients trea-
ted with TAVI, the presence of moderate or
severe tricuspid regurgitation and RV dilata-
tion have been independently associated with
increased 1-year mortality [4]. Finally, the
presence of secondary pulmonary hyperten-
sion (PH) and RV failure in AS patients has
been also associated with an increased peri-
operative risk [5].
There is paucity of data regarding RV func-
tion in patients with severe AS and mild degrees
of secondary PH being considered for possible
TAVI. We, therefore, examined patients referred
for TAVI to describe RV echocardiographic
measurements to determine possible RV
abnormalities in the presence of PH secondary
to severe AS (sAS).
METHODS
In this retrospective case series, echocardio-
graphic data from patients with sAS and pre-
served left ventricular systolic function from
2009 through 2011 were collected. This article is
based on previously conducted studies and does
not involve any new studies of human or ani-
mal subjects performed by any of the authors.
The University of Cincinnati College of Medi-
cine Institutional Review Board Committee
approved data collection for this study.
Inclusion criteria required that all patients at
the time of the echocardiographic study were in
normal sinus rhythm. In addition, there had to
be good visualization of the left and right ven-
tricular endocardium for tracing of end diastolic
and systolic cavity. Patients with atrial fibrilla-
tion or rhythm abnormalities, mitral annular
calcification, mitral valve stenosis, or previous
valvular replacement surgery were excluded.
Two-dimensional echocardiographic studies
were performed using commercially available
systems (Vivid 7 and 9; GE Medical Systems,
Milwaukee, WI, USA). The following echocar-
diographic parameters were measured: (A) aor-
tic valve gradient and aortic dimensional index;
(B) pulmonary artery systolic pressure (PASP);
(C) LV ejection fraction, mass index, as well as
end-systolic and end-diastolic volumes; (D) Left
atrial volume index; (E) RV fractional area
change, systolic velocity, end-systolic and
end-diastolic area; (F) tricuspid annular plane
systolic excursion (TAPSE), TA tissue Doppler
systolic velocity (TA TDI s’), maximum tricuspid
regurgitation velocity and right atrial pressure.
The commercially available software Merge
Cardio Workstation (Merge Healthcare) was
used to calculate all echocardiographic mea-
surements determined by a single observer.
Categorical data are presented as frequencies
and continuous data are presented as
mean ± standard deviation.
RESULTS
In this preliminary study, a complete
transthoracic echocardiogram with adequate
left and right endocardial border resolution to
allow determination of end systolic and dias-
tolic measurements as well as TA-motion with
M-mode and tissue Doppler of tricuspid valve
and inferior vena cava were performed in 30
patients [mean age 82 ± 11 years, 12 men
(40%)] with severe aortic stenosis. Nine-
ty-seven percent of the study population were
older than 65 years. After evaluating PASP
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measurements, we found that 16 (53%) indi-
viduals had PH.
Echocardiographic parameters of PH patients
are listed in Table 1. The mean aortic valve
gradient of the studied population was
56 ± 20 mmHg and the dimensional index was
0.2 ± 0.1. As expected, in this sAS patient pop-
ulation both left ventricular mass index
(281 ± 75 g/m2) and left atrial volume index
(89 ± 23 mL/m2) values were significantly ele-
vated. RV end systolic (8 ± 4 cm2) and end
diastolic (17 ± 4 cm2) areas, as well as RV frac-
tional area change values were within the nor-
mal range (57% ± 16%). However, longitudinal
measures of RV systolic function such as tri-
cuspid annular plane systolic excursion
(1.9 ± 0.5 cm) and TA TDI s’ (10 ± 2 cm/s) were
clearly reduced with just mild elevations in
PASP (54 ± 7 mmHg).
DISCUSSION
These preliminary results appear to suggest that
subclinical RV dysfunction is present in sAS
patients with mild degrees of PH, which is
clinically critical considering that PH is not only
an independent predictor of late TAVI mortality
[6], but also increases operative mortality while
reducing long-term survival [7]. Furthermore,
subclinical RV dysfunction has been identified
as an adverse predictor of clinical outcomes in
PH patients [8].
The prevalence of severe pulmonary hyper-
tension in patients with severe aortic valve
stenosis has been reported as high as 29% using
invasive hemodynamic monitoring prior to sur-
gical aortic valve replacement (SAVR) [9]. Recent
data from Barbash et al., showed that pulmonary
hypertension was a frequent co-morbidity found
Table 1 Echocardiographic data of the study population
Variables Mean value (–SD) Range
Aortic valve gradient (mmHg) 56 (20) 28–99
Aortic dimensional index 0.2 (0.1) 0.1–0.3
PASP (mmHg) 54 (7) 45–66
LVEF (%) 66 (19) 32–92
LV-end systolic volume (cm3) 37 (31) 5–102
LV-end diastolic volume (cm3) 100 (43) 45–192
LV mass index (g/m2) 281 (75) 175–437
LA volume index (ml/m2) 89 (23) 46–130
RV-end systolic area (cm2) 8 (4) 4–19
RV-end diastolic area (cm2) 17 (4) 11–27
RV fractional area change (%) 57 (16) 29–79
TAPSE (cm) 1.9 (0.5) 1.1–2.6
TA TDI s’ (cm/s) 10 (2) 6–13
MaxTR (cm/s) 3.3 (0.2) 3.0–3.8
RAP (mmHg) 11 (3) 10–19
PASP pulmonary artery systolic pressure, LV left ventricle, LA left atrium, RV right ventricle, TAPSE tricuspid annular
plane systolic excursion, TA TDI s’ tricuspid annular tissue Doppler imaging systolic velocity, MaxTR maximum tricuspid
regurgitation velocity, RAP right atrial pressure
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in patients with severe aortic stenosis referred for
TAVR. In addition, these investigators found that
significantly elevated pulmonary artery pressures
at baseline was a poor prognostic factor when
performing preprocedural assessment of the
patients [10]. The prevalence of PH in our case
series (56%) was higher than previously pub-
lished by these authors.
Musa and collaborators have recently
explored the impact of TAVI and SAVR upon RV
function in patients with sAS using cardiovas-
cular magnetic resonance [11]. Interestingly,
they found that TAVI had no adverse impact on
RV function and volume. Unfortunately, we
lack post-TAVI echocardiographic information
for most of patients included in our study.
Nevertheless, further studies are encouraged to
determine whether or not TAVI has any adverse
beneficial impact upon right ventricular
echocardiographic parameters.
Even though there have been some varia-
tions in terms of what is expected as normal
with regards to longitudinal measures of RV
systolic function, our laboratory has consis-
tently shown the linear relationship between
these measures and RV fractional area change.
In prior reported studies, a TAPSE[2 cm and a
TD TDI s’ [12 cm/s correlated with a RV frac-
tional area change[55% [12, 13].
Some limitations need to be acknowledged in
our study. First, this is a retrospective case series
study; however, the main goal was met. Second,
there was only a small number of patients
included for analysis. Third, the original data-
base missed important data, such as strain
imaging and invasive hemodynamic informa-
tion. Furthermore, based on the pre-specified
exclusion criteria no assumptions can be made
on how atrial fibrillation or rhythm abnormali-
ties, mitral annular calcification, mitral valve
stenosis, or prior valvular replacement surgery
could affect the reliability of our study findings.
CONCLUSION
Reductions in longitudinal measures of RV sys-
tolic function suggestive of subclinical RV dys-
function could affect clinical outcomes in sAS
patients, despite normal reference standard
values for RV size and fractional area change in
mild degrees of PH. Additional studies are now
required to determine whether subclinical RV
dysfunction in sAS patients with mild PH
undergoing TAVI might not only be an indirect
measurement of AS severity, but also an
important tool in predicting overall clinical
outcomes.
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